Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Inflammatory Arthritis and Autoimmune Inflammatory Systemic Diseases: From Bench to...
share announcement

Inflammatory Arthritis and Autoimmune Inflammatory Systemic Diseases: From Bench to Bedside and Back

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 11219

Special Issue Editors

Dr. Marco Sebastiani

E-Mail Website
Guest Editor
Rheumatology Unit, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, 41121 Modena, Italy
Interests: rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; vasculitis; connective tissue diseases
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Giovanni Lapadula

E-Mail Website
Guest Editor
Rheumatology Unit, Medical School, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
Interests: rheumatology; rheumatoid arthritis; clinical rheumatology; autoinflammatory diseases; chronic inflammation; biotherapeutics; psoriatic arthritis; ankylosing spondylitis; systemic sclerosis; adult rheumatology

Special Issue Information

Dear Colleagues,

This Special Issue is a collection of selected papers from the 2022 International GISEA Symposium (https://www.gisea.eu/). The Journal of Clinical Medicine (JCM) is providing an opportunity to publish selected data presented at the annual meeting.

Rheumatology has experienced a series of new discoveries since the early 2000s, both in terms of pathogenesis of inflammatory rheumatological diseases and in therapeutic terms, with the appearance and marketing of numerous drugs with original and innovative mechanisms of action. All this has allowed better patient care, making it possible to achieve goals that were unthinkable until 20 years ago and enabling hope, even to patients who are most refractory to conventional treatments. Most of the knowledge relating to new drugs and new treatment strategies comes from the analysis of the data of the registers, which allow us to evaluate a large number of patients treated according to the usual clinical practice. GISEA is the Italian national register of patients treated with innovative therapies that collects data from thousands of patients and that has contributed over the years, through numerous scientific works, to broaden our knowledge in this field. The annual GISEA conference is an opportunity for discussion between experts and training for rheumatologists active in the area: this takes place through reports held by recognized national and international experts, and discussions and interactions with the public.

Dr. Marco Sebastiani
Prof. Dr. Giovanni Lapadula
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • vasculitis
  • connective tissue diseases

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 581 KiB  
Article
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
by Salvatore D’Angelo, Enrico Tirri, Angela Maria Giardino, Marco Mattucci-Cerinic, Lorenzo Dagna, Leonardo Santo, Francesco Ciccia, Bruno Frediani, Marcello Govoni, Francesca Bobbio Pallavicini, Rosa Daniela Grembiale, Andrea Delle Sedie, Rita Mulè, Francesco Paolo Cantatore, Rosario Foti, Elisa Gremese, Paola Conigliaro, Fausto Salaffi, Ombretta Viapiana, Alberto Cauli, Roberto Giacomelli, Luisa Arcarese, Giuliana Guggino, Romualdo Russo, Amy Puenpatom, Domenico Capocotta, Francesca Nacci, Maria Grazia Anelli, Valentina Picerno, Corrado Binetti and Florenzo Iannoneadd Show full author list remove Hide full author list
J. Clin. Med. 2022, 11(14), 4178; https://doi.org/10.3390/jcm11144178 - 19 Jul 2022
Cited by 6 | Viewed by 2663
Abstract
In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the [...] Read more.
In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy. Full article
(This article belongs to the Special Issue Inflammatory Arthritis and Autoimmune Inflammatory Systemic Diseases: From Bench to Bedside and Back)
►▼ Show Figures

Figure 1

Review

Jump to: Research

10 pages, 1137 KiB  
Review
Clinical Trials in Chronic Arthritic Diseases with Underestimated Impact of Placebo Effects on Study Size Calculation
by Katharina Richetti, Jennifer Gebetsberger, Werner Streif and Michael Schirmer
J. Clin. Med. 2023, 12(2), 429; https://doi.org/10.3390/jcm12020429 - 05 Jan 2023
Viewed by 1564
Abstract
Whether and to which extent placebo treatment in double-blinded randomized controlled clinical trials is effective in chronic arthritic diseases has not been studied before. Therefore, a systematic literature search was undertaken to detect eligible trials. Demographic data of the placebo groups as well [...] Read more.
Whether and to which extent placebo treatment in double-blinded randomized controlled clinical trials is effective in chronic arthritic diseases has not been studied before. Therefore, a systematic literature search was undertaken to detect eligible trials. Demographic data of the placebo groups as well as concomitant and previous disease outcomes were collected. Analyses of significant bivariate correlations and linear regression between clinical endpoints and characteristics of the placebo groups were performed. A total of 152 double-blinded randomized controlled studies, including 21,616 participants in the placebo groups, was analyzed. The results of bivariate correlations and linear regressions revealed significant positive associations between responses in the placebo groups and the following factors: (i) naïvety of previous treatment and (ii) early stage of disease. In addition to the clinical relevance, the results support the importance of the placebo effect on study size calculations, and will allow an optimized calculation of patients’ numbers for early placebo-controlled trials conducted in patients with chronic arthritic diseases. Full article
(This article belongs to the Special Issue Inflammatory Arthritis and Autoimmune Inflammatory Systemic Diseases: From Bench to Bedside and Back)
►▼ Show Figures

Figure 1

10 pages, 1053 KiB  
Review
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium
by Fulvia Ceccarelli, Marcello Govoni, Matteo Piga, Giulia Cassone, Francesco Paolo Cantatore, Giulio Olivieri, Alberto Cauli, Ennio Giulio Favalli, Fabiola Atzeni, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula and Fabrizio Conti
J. Clin. Med. 2022, 11(20), 6016; https://doi.org/10.3390/jcm11206016 - 12 Oct 2022
Cited by 8 | Viewed by 6083
Abstract
Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI [...] Read more.
Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations’ development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients’ quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium. Full article
(This article belongs to the Special Issue Inflammatory Arthritis and Autoimmune Inflammatory Systemic Diseases: From Bench to Bedside and Back)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop